Company Valuation: Beijing SL Pharmaceutical Co., Ltd.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 10,376 11,106 8,445 10,469 7,674 7,572
Change - 7.03% -23.96% 23.97% -26.69% -1.34%
Enterprise Value (EV) 1 8,939 9,472 6,992 8,390 5,692 6,430
Change - 5.96% -26.19% 20.01% -32.16% 12.97%
P/E 28.1x 26.4x 35.7x 24.9x -107x -21.7x
PBR 2.09x 2.09x 1.54x 1.8x 1.38x 1.46x
PEG - 1.9x -0.8x 0.3x 1x -0x
Capitalization / Revenue 9.32x 9.14x 8.04x 10.3x 11.6x 12.1x
EV / Revenue 8.03x 7.8x 6.66x 8.24x 8.62x 10.3x
EV / EBITDA 37.3x 30.3x 27.2x 23.5x 31.5x 40.4x
EV / EBIT 59.6x 44.6x 48.7x 39.7x 206x -838x
EV / FCF 94.3x 83x 57.6x 66.4x -21.9x -176x
FCF Yield 1.06% 1.2% 1.74% 1.51% -4.57% -0.57%
Dividend per Share 2 0.1 0.1 0.1 0.15 0.02 0.01
Rate of return 0.99% 0.93% 1.22% 1.47% 0.27% 0.14%
EPS 2 0.36 0.41 0.23 0.41 -0.07 -0.34
Distribution rate 27.8% 24.4% 43.5% 36.6% -28.6% -2.94%
Net sales 1 1,113 1,215 1,050 1,018 660.4 623.6
EBITDA 1 239.4 312.1 257.2 356.5 180.6 159.1
EBIT 1 149.9 212.5 143.7 211.1 27.65 -7.676
Net income 1 364.7 425.9 234.4 416.7 -74.07 -347.2
Net Debt 1 -1,437 -1,634 -1,453 -2,078 -1,982 -1,141
Reference price 2 10.100 10.810 8.220 10.190 7.470 7.370
Nbr of stocks (in thousands) 1,027,350 1,027,350 1,027,350 1,027,350 1,027,350 1,027,350
Announcement Date 4/25/21 4/24/22 4/24/23 4/22/24 4/20/25 4/27/26
1CNY in Million2CNY
Estimates


P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 686M
39.41x13.36x28.32x0.51% 1,200B
36.94x6.65x18.71x1.97% 651B
36.49x8.39x17.36x2.41% 506B
21.41x5.17x12.95x2.53% 377B
94.91x5.47x23.3x2.54% 330B
22.98x5.56x13.52x2.87% 288B
23.04x4.63x13.15x1.9% 272B
22.49x6.97x12.81x2.32% 236B
-39.14x7.25x45.66x1.98% 206B
Average 28.72x 7.05x 20.64x 2.11% 407B
Weighted average by Cap. 34.25x 8.45x 21.50x 1.77%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Beijing SL Pharmaceutical Co., Ltd.

Historical PBR trend

Valuation ratios - PBR - Beijing SL Pharmaceutical Co., Ltd.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Beijing SL Pharmaceutical Co., Ltd.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Beijing SL Pharmaceutical Co., Ltd.

  1. Stock Market
  2. Stocks
  3. 002038 Stock
  4. Valuation Beijing SL Pharmaceutical Co., Ltd.